Opendata, web and dolomites

VasQ

An innovative external brace to ensure patency and maturity of arteriovenous fistulas in haemodialysis patients.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "VasQ" data sheet

The following table provides information about the project.

Coordinator
LAMINATE MEDICAL TECHNOLOGIES LTD 

Organization address
address: 24 RAUL WALLENBERG STREET
city: TEL AVIV
postcode: 6971921
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.laminatemedical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2016-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LAMINATE MEDICAL TECHNOLOGIES LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Arteriovenous Fistulas (AVF), the process of joining a vein to an artery, is the gold standard for both vascular access (VA) and haemodialysis (HD) in end-stage renal disease (ESRD) patients; however, the procedure is fraught with post-surgical complications, leading to a 65% rate of usability 3-months after the surgery. VasQ is an external support device which wraps the vein to provide structural support, and braces it against the artery to improve flow properties; hence, it presents a drastic improvement over both conventional AVF procedures and the competing alternative technologies. By providing structural support to the vein in the AVF, and bracing the site where the artery and vein are joined at an optimal angle, VasQ prevents the complications relating to a vein being subjected to arterial conditions (stenosis, aneurysm, rupture), and the flow-pattern problems (thrombosis, shear force complications). VasQ improves the maturation success rate to 87% at 3 months and has shown a 3x improvement in flow rates of the AVF over the accepted minimum standard for maturation, and a 60% improvement in venous diameter over the accepted minimum standard within 3 months. The implementation of VasQ does not alter the AVF procedure, ensuring that the surgeons do not need to learn a new work process. Overall, VasQ provides repeatable, superior results to both unsupported AVF’s and alternative procedures, and improves the long-term usability of AVF’s, which reduces the cost to patients and healthcare providers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VASQ" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VASQ" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More